Medical Ikkou Group Co., Ltd. AI Stock Analysis
Want to see JP:3353 full AI Analyst Report?
Medical Ikkou Group Co., Ltd. (3353) AI Stock Analysis
Medical Ikkou Group Co., Ltd.
(TSE/TYO:3353)
The stock's attractive valuation (P/E 7.02, 4.36% yield) and strong balance sheet are significant positives. However, these are heavily counterbalanced by extremely weak technical momentum, with the price trading below all major moving averages and deeply oversold oscillators. Moderate but stable financial performance with thin margins provides a neutral foundation, resulting in a slightly above-average overall score.
Medical Ikkou Group Co., Ltd. (3353) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 10.11B
- Dividend Yield
- 4.47%
- Average Volume (3M)
- 2,056
- Price to Earnings (P/E)
- 6.9
- Beta (1Y)
- 0.29
- Revenue Growth
- 6.91%
- EPS Growth
- 33.61%
- Country
- Japan
- Employees
- 1,608
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Conglomerates
Medical Ikkou Group Co., Ltd. Business Overview & Revenue Model
Company Description
Medical Ikkou Group Co.,Ltd. is a Japanese enterprise primarily known for managing dispensing pharmacies across the nation. Beyond its extensive pharmacy operations, the company diversified its activities to include the management of various care fac...
How the Company Makes Money
Medical Ikkou Group Co., Ltd. makes money mainly by operating dispensing pharmacies that fill outpatient prescriptions issued by medical institutions. Revenue is generated when the company dispenses prescription medicines and bills the applicable pay...
Medical Ikkou Group Co., Ltd. Financial Statement Overview
Summary
Solid balance sheet (Score 85) with significantly reduced leverage and growing equity offsets thinner profitability (Income Score 70) and modest cash flow conversion (Cash Flow Score 60). Overall financial health is stable with improving returns, but low margins and high capex limit upside.
Income Statement
70PositiveBalance Sheet
85Very PositiveCash Flow
60Neutral| Breakdown | TTM | Feb 2026 | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 54.98B | 54.98B | 48.39B | 39.90B | 33.90B | 33.60B |
| Gross Profit | 6.36B | 6.36B | 5.61B | 4.38B | 2.97B | 3.37B |
| EBITDA | 2.63B | 2.63B | 2.46B | 2.34B | 1.78B | 2.15B |
| Net Income | 1.28B | 1.28B | 1.13B | 1.04B | 759.60M | 852.33M |
Balance Sheet | ||||||
| Total Assets | 37.52B | 37.52B | 34.23B | 31.66B | 27.51B | 29.09B |
| Cash, Cash Equivalents and Short-Term Investments | 6.12B | 6.12B | 6.77B | 7.70B | 6.44B | 7.99B |
| Total Debt | 10.36B | 10.36B | 10.04B | 9.60B | 9.15B | 11.35B |
| Total Liabilities | 21.24B | 21.24B | 19.52B | 17.82B | 14.90B | 17.17B |
| Stockholders Equity | 15.63B | 15.63B | 14.10B | 13.24B | 12.05B | 11.38B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 219.98M | 201.34M | 3.97B | 995.40M | 812.29M |
| Operating Cash Flow | 0 | 1.21B | 1.20B | 4.28B | 1.31B | 1.14B |
| Investing Cash Flow | 0 | -1.81B | -1.13B | -3.22B | -477.52M | 539.48M |
| Financing Cash Flow | 0 | -283.62M | -1.03B | 277.76M | -2.37B | -690.26M |
Medical Ikkou Group Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3353, the sentiment is Negative. The current price of 2686.00 is below the 20-day moving average (MA) of 2750.05, below the 50-day MA of 2780.46, and below the 200-day MA of 2787.35, indicating a bearish trend. The MACD of -23.60 indicates Positive momentum. The RSI at 34.48 is Neutral, neither overbought nor oversold. The STOCH value of 56.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3353.
Medical Ikkou Group Co., Ltd. Peers Comparison
Overall Rating
JP:750972Outperform
JP:924866.8Neutral
JP:335365Neutral
JP:711957Neutral
JP:246256Neutral
JP:683847Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | JPY 6.44B | 5.02 | ― | 3.56% | 0.18% | -2.47% | |
| 67Neutral | JPY 14.05B | 5.17 | ― | 3.88% | -4.53% | -37.26% | |
| 65Neutral | JPY 9.40B | 6.93 | ― | 4.47% | 6.91% | 33.61% | |
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| 57Neutral | JPY 20.67B | 17.30 | ― | 2.10% | -1.37% | 48.83% | |
| 56Neutral | JPY 28.15B | 12.81 | ― | 4.10% | 5.94% | -0.10% | |
| 47Neutral | JPY 9.29B | 18.49 | ― | 0.99% | ― | ― |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:3353 | Medical Ikkou Group Co., Ltd. | 2686.00 | 121.60 | 4.74% | |
| JP:2462 | LIKE, Inc. | 1464.00 | 20.97 | 1.45% | |
| JP:6838 | Tamagawa Holdings Co., Ltd. | 1009.00 | 176.92 | 21.26% | |
| JP:7119 | halmek holdings Co.,Ltd. | 1855.00 | 560.19 | 43.26% | |
| JP:7509 | I. A Group Corporation | 4350.00 | 446.87 | 11.45% | |
| JP:9248 | People, Dreams & Technologies Group Co., Ltd. | 1547.00 | 34.07 | 2.25% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
